Kronisk bihulebetændelse og type 2-sygdom

Kasper Aanæs; Mikkel Christian Alanin; Elisabeth Arndal; Vibeke Backer; Eva Kirkegaard Kiær; Niclas Rubek; Henrik Bredahl Sørensen; Christian von Buchwald

Kronisk bihulebetændelse og type 2-sygdom

Kasper Aanæs, Mikkel Christian Alanin, Elisabeth Arndal, Vibeke Backer, Eva Kirkegaard Kiær, Niclas Rubek, Henrik Bredahl Sørensen, Christian von Buchwald

1 Citationer (Scopus)

Abstract

Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.

Bidragets oversatte titel	Chronic rhinosinusitisand type 2 disease
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	184
Udgave nummer	10
ISSN	0041-5782
Status	Udgivet - 7 mar. 2022

Emneord

Chronic Disease
Humans
Nasal Polyps/complications
Quality of Life
Rhinitis/complications
Sinusitis/complications

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{703296894d1a408f98dec11d603d66fe,

title = "Kronisk bihulebet{\ae}ndelse og type 2-sygdom",

abstract = "Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.",

keywords = "Chronic Disease, Humans, Nasal Polyps/complications, Quality of Life, Rhinitis/complications, Sinusitis/complications",

author = "Kasper Aan{\ae}s and Alanin, {Mikkel Christian} and Elisabeth Arndal and Vibeke Backer and Ki{\ae}r, {Eva Kirkegaard} and Niclas Rubek and S{\o}rensen, {Henrik Bredahl} and {von Buchwald}, Christian",

year = "2022",

month = mar,

day = "7",

language = "Dansk",

volume = "184",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "10",

}

TY - JOUR

T1 - Kronisk bihulebetændelse og type 2-sygdom

AU - Aanæs, Kasper

AU - Alanin, Mikkel Christian

AU - Arndal, Elisabeth

AU - Backer, Vibeke

AU - Kiær, Eva Kirkegaard

AU - Rubek, Niclas

AU - Sørensen, Henrik Bredahl

AU - von Buchwald, Christian

PY - 2022/3/7

Y1 - 2022/3/7

N2 - Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.

AB - Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.

KW - Chronic Disease

KW - Humans

KW - Nasal Polyps/complications

KW - Quality of Life

KW - Rhinitis/complications

KW - Sinusitis/complications

UR - http://www.scopus.com/inward/record.url?scp=85126844414&partnerID=8YFLogxK

M3 - Review

C2 - 35315753

SN - 0041-5782

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 10

ER -

Kronisk bihulebetændelse og type 2-sygdom

Abstract

Emneord

Andre filer og links

Fingeraftryk

Citationsformater